8/10/2019 Adverse and Toxic Drug Reactions
1/49
Pharmacotherapeutic
complications
2009
Martin trba, PharmD. PhD.Department of Pharmacology
8/10/2019 Adverse and Toxic Drug Reactions
2/49
Pharmacotherapeuticcomplications
Adverse and toxic effects of drugsDrug interactions (drug-drug) Food and drug interactions
Drug dependence and abuseThere is no ideal drug which is free of risks ofpharmacotherapeutic complications The knowledge and understanding of
pharmacotherapeutic risks is essential for safe useof drugs in clinical practice
Consequences of pharmacotherapeutic complications Health related Legal Ethic
Economic
8/10/2019 Adverse and Toxic Drug Reactions
3/49
Adverse and toxic
effects of drugs
8/10/2019 Adverse and Toxic Drug Reactions
4/49
Adverse toxic reactions terminology
Is far from being unified Unwanted, adverse, side or toxiceffects/reactions Effects (of drugs) vs reaction (of patients)
adverse drug reaction (WHO def.) = unintended andnox
ious (harmful) response that occurs at normal dosesof the drug used for prophylaxis, diagnosis andtreatment of diseases A, B, C, D, E CLASSIFICATION !!! They often require change of dose/dosage schedule or drug
withdrawal. Sometimes Side effects ( collateral effects) are distinguished theweak form of the adverse effect which is unpleasant but generallyacceptable. The marked changes in dosage schedule or drugwithdrawal are usually not necessarily.
E.g. weak sedation with H1-antihistamines, constipation with opioids, drymouth with antimuscarinics
Attention! The term side effects is often used as a synonym to adverseeffects.
8/10/2019 Adverse and Toxic Drug Reactions
5/49
Toxic drug reaction Unintended, primarily harmful and reactions occurring at high
(supratherapeutic) doses and/or after long treatment (acuteor chronic overdose).
Toxic effects are often associated with morphologic changes which might be irreversible .
Reasons:Iatrogenic intoxication medication error, critical situationswhen high drug doses are neededNon-compliance and patients errors (multiple pharm. prep. withsame active drug), self-administration (overdose) in childrenSuicidal attempts (antidepressants...)
Paracelsus: only the dose makes the difference between thedrug and poison
Precise preclinical characterization of toxic drug effects is amandatory part of the request for approval of the drug forclinical investigation and the same applies for final approvalfor its clinical use
Adverse toxic reactions
terminology
8/10/2019 Adverse and Toxic Drug Reactions
6/49
Adverse drug reactions
8/10/2019 Adverse and Toxic Drug Reactions
7/49
Adverse effectsType A (augmented)
Are induced by same pharmacological mechanisms as the therapeutic effects By increase of the therapeutic or other pharmacological effect of the drug
Is directly dose-dependent (or plasma concentration dependent) It is mostly associated with inappropriate dosage schedule (inappropriately
high dose and/or short dosing interval) It can arise from changes in drug pharmacokinetics (e.g., impaired drug
elimination or plasma protein binding) As a result of the pathology (kidney, liver failure and hypoalbuminemia) As a result of aging (e.g. Lower renal elimination in elderly)
It can arise from changes in drug pharmacodynamicsPredisposition due to the concomitant pathology pay appropriate attention on CONTRAINDICATIONSOr patient non-compliance (e.g. failure to follow all instructions)
Are well predictable with respect to both their clinical manifestation andprobability of onset
Type A is the most frequent type of adverse effects (76%)They have relatively less dangerous outcomes with lower rate of mortalit
8/10/2019 Adverse and Toxic Drug Reactions
8/49
Examples: Anticoagulants (e.g., wafarin, heparin) bleeding Antihypertensives (e.g.. 1 -antagonists) hypotension
Antidiabetics (e.g. insulin) - hypoglycemia 1-blockers (e.g. metoprolol)
Symptomatic heart failure inpatients with previous systolicdysfunctionBronchoconstriction in patients with COPD
Antiepileptics blocking Na+
channel (e.g., phenytoin) neurological symptoms - vertigo, ataxia, confusion
Intervention dose reduction in most cases, use of antagonist inserious circumstancesPrevention: dose titration, adverse effects monitoring,
pharmacotherapy monitoring (PK and PD principle)
Adverse effects
Type A (augmented)
8/10/2019 Adverse and Toxic Drug Reactions
9/49
Develop on the basis of: Immunological reaction on a drug (allergy ) Genetic predisposition (idiosyncratic reactions )Have no direct relationship to
the dose of the drug The pharmacological mechanism of drug action Are generally unexpected and therefore unpredictableThey appear with much lower frequency (0,1-0,01%)Have more serious clinical outcomes with higher overall mortalityIntervention: instant drug withdrawal, symptomatic treatment pharmacological approach in allergy: antihistamines, adrenalin
(epinephrine) , glucocorticoids Prevention: troublesome, the risks can be reduced by dutiful drug-related anamnesis, by avoiding certain drugs with known significantrisk of B-type reactions Allergy: dermatological testing, in vitro testing (mixed outcomes),
desensitization Idiosyncratic reactions: genotyping, phenotyping
Adverse effectsType B (bizzare)
8/10/2019 Adverse and Toxic Drug Reactions
10/49
Adverse effects - T ype BAllergic reactions
Based on immunological mechanismThey require previous exposition before actual manifestationMolecular weight of most drugs is low (Mr
8/10/2019 Adverse and Toxic Drug Reactions
11/49
Route of administration impact Higher probability of both occurrence and increased severity
after parenteral (injectional) administration !); mind the effectiveness of antigen presenting process
Relatively high probability after application on the skinSignificantly lower probability after p.o. administrationNot only a active substance can be responsible forallergic reactions excipients antimicrobial agents, preservants
- E.g., parabens- must be listed in the Summary of ProductCharacteristics (SPC!)
- In the case of known allergy to common excipients the genericprescription should be avoided
- Drug decomposition products, impurities etc.: they are undercontrol of the national authorities (FDA)
- appropriate storage, use and expiration should be followed
Adverse effects - T ype BAllergic reactions
8/10/2019 Adverse and Toxic Drug Reactions
12/49
They are divided according to the prevailingimmunological mechanism into 4 groups (Gell-Coombs classification system):
TYPE I (IgE-mediated, immediate reactions) TYPE II (cytotoxic reactions) TYPE III (immunocomplex reactions) TYPE IV (delayed, cell-mediated reactions)
Newer classification: Taking into account T-cell subtypes (Th1/Th2, Cytotox. T-cells), specificity of the cytokine signaling and differenteffectors (monocytes, eaosinophils, CD8 T-cells,neutrophils)
TYP IV a, b ,c, d
Adverse effects - T ype BAllergic reactions - classification
8/10/2019 Adverse and Toxic Drug Reactions
13/49
Sensitisation phase Immunogenic complex (drug-carrier) induces production of
specific IgE antibodies IgE ab is bound on the cell surface of mast cells and basophiles via
high affinity receptors Allergic reaction triggering
After re-exposition, the drug+carrier is directly bound on the IgE Cross-linking of the IgE Degranulation of the mast cells = release of histamine, leukotriens,
prostaglandins inflammatory reaction!Rubor, calor, dolor a tumor
Clinical manifestation: urticaria, itching, nose/eye hyperemiaand secretion, soft-tissue swelling, bronchospasm, anaphylacticreactionTime window: after previous sensitization the onset is very rapidone (seconds to minutes)Examples: penicilins, cephalosporins, quinolones, macrolides,
streptokinase, thiazides, salicylates and skeletal musclerelaxants, local anesthetics
Allergic reactions TYPE IIgE-mediated
8/10/2019 Adverse and Toxic Drug Reactions
14/49
Anaphylactic reactions More complex (multiorgan) and more serious type I reactions Onset mostly within 15 min after drug administration First symptoms : itching (mostly palmar, plantar a axilles) Thereafter: diffuse erythema (first on the trunk becomes
generalized), urticaria Soft-tissue edema (peri - orbital, -oral, - genital) Laryngeal edema (difficulties with speaking, swallowing, breathing) Pressure on the chest and dyspnoe bronchospasm Hypotension, arrhythmias 75% of cases are due to the penicillins
Anaphylactic shock Shock or shock-like status as a result of fully blown multiorgan
anaphylaxis with possible progression into the total collapse Lethal in 1-2% cases Risk factors: higher dose, asthma, atopic anamnesis, elderly
pharmacological treatment: adrenalin + glucocorticoids i.v.,antihistamines
Allergic reactions TYPE IIgE-mediated
8/10/2019 Adverse and Toxic Drug Reactions
15/49
Drug (hapten) is bound on the surface of targetcells (these are carri ers)
Antibody production: IgG (IgG1 and IgG3), rarely
IgM After re-exposition the drug is bound again on thecell surface and IgG is attachedThe activation of the complement system and NKcells execute the cytotoxic reactions
The cell is destructed and/or taken up by the RESThe main target cells: erythrocytes, leukocytes,trombocytes, hematopoietic cells Clinical outcome: anemia or - peniaDrugs: quinidine, heparin, sulfonamides,cephalosporins, penici llins, anticonvulsants.
Allergic reactions TYPE IICytotoxic
8/10/2019 Adverse and Toxic Drug Reactions
16/49
Hemolytic anemia Associated with cephalosporins, penicilins, quinidine,
levodopa, methyldopa, some NSAIDs
Symptoms: like in other anemia + jaundice, dark urine Lab. picture: erythrocytopenia, reticulocytosis and
billirubin (unconjugated); hemoglobin a hemosiderin inurine
Thrombocytopenia Associated with heparin (up to 5% patients), quinine
quinidine, sulfonamides and biologicals (-mabs, e.g.,bevacizumab)
Symptoms: petechial bleeding to the skin and mucosa,GIT and urogenital tract bleeding
Reversibility: in usually in 3-5 days
Allergic reactions TYPE IICytotoxic
8/10/2019 Adverse and Toxic Drug Reactions
17/49
Allergic reactions TYPE IIIImmunocomplex reactions
Drug-carrier or drug as a chimeric protein inducesproduction of IgG antibodies
Formation of IgG-drug(carrier) complexesNormally these complexes are cleared by the RESwith only some decrease in the clinical response
In some circumstances (huge amount of complexes,deficient decomposition system) it results todevelopment of symptomatic reactionTime window: 1-3 weeks after expositionEpidemiology: 1-3:100 000 patients
8/10/2019 Adverse and Toxic Drug Reactions
18/49
Clinical manifestation: vasculitis and/or serum sickness,Urticaria, dermatol. affections, pruritus, fever, arthritis/arthralgia,glomerulonephritis, lyfmadenopathy
Serum sickness first described after passive immunizationwith animal serumWithin 4-10 day the abs were produced and formed complexeswith antigenic proteins.These complexes were deposited in postcapillary venules andattracted neutrophils
Development of inflammation with release of proteolyticenzymes destructing vessel and surrounding tissue
Drugs: chimeric abs (e.g., infliximab) or cephalosporins(cefaclor, cefalexin), amoxicillin,sulfamethoxazole/trimethoprim, NSAIDs, amiodaron
Allergic reactions TYPE IIIImmunocomplex reactions
8/10/2019 Adverse and Toxic Drug Reactions
19/49
Cellular reaction mediated by T-cellsGeneral principle: drug-carrier complex is presented by
APC to T-cells with their following clonal proliferation After re-exposition the drug gets into contact with T-cells with release of specific cytokines and inflammatorymediators which activate the target cellsClinical manifestation : mostly drug-related contact
dermatitis (rash) in many forms + pruritus, tuberculinreaction, maculopapular exanthema or e.g. allergichepatitisDrugs: aminoglycosides, penicillins.. Time window: 2-8 days
Allergic reactions TYPE IVDelayed, cell-mediated reaction
8/10/2019 Adverse and Toxic Drug Reactions
20/49
8/10/2019 Adverse and Toxic Drug Reactions
21/49
Pseudoalergic reactions
Are NOT immune reactionsThe are induced by direct activation of mast cells or bydisplacing histamine from granules
IgE are NOT increased Are as frequent as true type I reactions (IgE-mediated)Clinical manifestation is very close or evenindistinguishable from type I reactions
Mostly less severe (erythema, urticaria) Onset can be slower then in true type I May require higher doses Anaphylactoid forms can occur
Drugs: NSAIDs, vancomycin, opiates, radiocontrast
agents
8/10/2019 Adverse and Toxic Drug Reactions
22/49
Pseudoalergic urticaria
8/10/2019 Adverse and Toxic Drug Reactions
23/49
Do not require any prior sensitization Are primarily genetically determined
deviations in the human metabolism orbiotransformation of the drugs atypical acetylcholinesterase (AChE) abnormally
slow degradation of the suxamethonium
(depolarizing peripheral myorelaxans) Apnoe is lasting up to 2 hours instead of 2minDeficient glucosa-6-phosphate dehydrogenase higher susceptibility of Ery to hemolytic anemiadevelopment ( e.g., in quinidine)
Adverse effectsType B idiosyncratic reactions
8/10/2019 Adverse and Toxic Drug Reactions
24/49
Examples of Type A a B adverse reactions
Drug Type A Type Bampicillin pseudomembranous
collitisInterstitialnephritis
chlorpromazine sedation hepatotoxicity
naproxen Peptic ulcerdevelopment agranulocytosis
8/10/2019 Adverse and Toxic Drug Reactions
25/49
Adverse effectsType C Chronic (continous) use Are not as frequent as type AThey are mostly associated with cumulative-long termexposition inducing a toxic response Mostly the accumulation is not humoral but is that of
functional and/or ultrastructural changes induced by a drugDirect relationship to the cumulative doseExample: suppression of the hypothalamus-pituitary gland-adrenal cortex by long term systemic treatment withglucocorticoids
Toxicity of the drug after long-term treatment with therapeuticdoses Analgesic (NSAID) nephropathy interstitial nephritis,papillary sclerosis, necrosis, Mechanism: unclear, deficit of prostaglandins?! NSAIDs
inhibit their formation
8/10/2019 Adverse and Toxic Drug Reactions
26/49
Adverse effectsType C Chronic (continous) use
Anthracycline cardiotoxicity with increasingcumulative dose the degenerative changeswithin cardiomyocytes occurs (loss ofmyofibrils, vacuolization of cytoplasm, dilated cardiomyopathy with HF
Ethiopathogenesis: unknown, ROS?,mitochondriopathy, apoptosis.
Treatment : troublesome, largely irreversible in highercumulative doses
General prevention : cumulative dose reduction,limitation of time of exposure, monitoring, preventionof non-compliance and drug abuse
8/10/2019 Adverse and Toxic Drug Reactions
27/49
Adverse effectsType D Delayed
They manifest themselves withsignificant delay Teratogenesis, Mutagenesis/cancerogenesis others: e.g., tardive dyskinesis
during L-DOPA Parkinson diseasetreatment
8/10/2019 Adverse and Toxic Drug Reactions
28/49
Drug induced deviation from normal prenatal developmentTime window: from zygota to birth
Possible consequences: embryo/fetus death, morphologicmalformations, functional defects and defects (incl. behavioral),developmental retardation
Prerequisite: penetration of placental barrier Small molecules (Mr< 500), lipophilic enough Utilization of endogenous transporting mechanisms Protective mechanisms: efflux transporters (P-gp) and CYP450
According to the materno-fetal distribution we distinguish drugs into3 groups: Homogenous distribution between mother and fetus: amoxicillin,
morphine, paracetamol, nitrazepam Higher concentration in foetus: valproate, ketamine, diazepam Higher concentration in mother: prazosin, furosemide
Adverse effectsType D Teratogenicity
8/10/2019 Adverse and Toxic Drug Reactions
29/49
Teratogenic effects largely depends on the phaseof intrauterine development Blastogenesis (0.-14. day) mostly dead, or damage is
compensated without further consequencesOrganogenesis (15.-90. day ) gross anatomicmalformations of different type
Fetal development (90.-280. day) no gross anatomic butrather different functional deficits of the target tissue (oftenCNS)
All drugs must be carefully tested for teratogenicityduring their preclinical development At least two animal species (one rodent and one non-
rodent)
Interspecies differences in morphology of placenta
Adverse effectsType D Teratogenicity
8/10/2019 Adverse and Toxic Drug Reactions
30/49
Certain teratogens Thalidomide phocomelia (flipper -like hands) Antifolates abortus, suppression of hematopoiesis Isoretinoin and vitamin A (high doses) heart malformation and
hydrocephalon
Warfarin chondrodysplasa, facial abnormalities, CNS defects Valproate defect of the neural tube: spina bifida
Teratogens suspect Tetracyclines teeth and bone defects Lithium heart malformation Glucocorticoids growth retardation, cleft palate ACE-inhibitors renal failure in fetus, oligohydramnion, fetal
hypotension, pulmonary hypoplasia or intrauterine death Phenytoin fetal hydantoin syndrome (craniofacial malformations,
microcephalon and cleft palate) Carbamazepine craniofacial malformations
Adverse effectsType D Teratogenicity
8/10/2019 Adverse and Toxic Drug Reactions
31/49
Adverse effects
Type D Teratogenicitythalidomide
http://upload.wikimedia.org/wikipedia/it/0/05/Talidomide_struttura.PNG8/10/2019 Adverse and Toxic Drug Reactions
32/49
Mutation = suddenly occurring and persisting change in the genomewhich is spreading further by cell replication
Some mutations may impair tight regulation of the cellular proliferation anddifferentiation resulting into the tumor formation carcinogenesis
60-70% of carcinogenic events are induced by chemical compounds (i.e.also with drugs)
This is specifically important for most of anticancer drugs , especially forthose directly interacting with DNA alkylating cytostatics, cisplatin etc Risk of secondary malignancies !!!
Test for mutagenicity: in vitro Ames test cultivation of S. typhimurium, i.e.strain which is unable to biosynthesize histidine (it must be supplied in themedia).upon exposure to drug in histidine -free media it is soughtwhether any drug-induced mutation can allow the bacteria to synthesizehistidine again
In vivo testing for carcinogenicity long-lasting, time and work-consumingtests, sometimes uneasy to predict translatability to humans (applies for
suspicious drug intended for long-term use)
Adverse effects Type D mutagenicity and carcinogenicity
8/10/2019 Adverse and Toxic Drug Reactions
33/49
Drug withdrawal syndromes and rebound phenomenonsTypical example sudden withdrawal of long termtherapy with -blockers can induce rebound tachycardia
and hypertension) Reason : Up-regulation of the receptors during chronictreatment)
Withdrawal of long-term systemic treatment withglucocorticoids adrenal insufficiency with risk of comaand deathWithdrawal syndrome in drug dependencePrevention: rather avoid abrupt withdrawals, slowdecrease in dose is helpful, avoid long treatment with
such drugs if possible
Adverse effectsType E End of use
8/10/2019 Adverse and Toxic Drug Reactions
34/49
Adverse drug effects inpractice:
According to Ritter (1995)Up to 80 % adverse reactions are of A type
3 % emergency cases 2-3 % in the care of GPs In the hospital they make up to 10-20 % of all treatments mortality rate is 0,3-1 %.
Additional costs!Risk factors:
age (newborns and young children, elderly) females liver and renal disease in anamnesis any such adverse reaction in anamnesis
Onset 1st-9th day after starting the pharmacotherapy
8/10/2019 Adverse and Toxic Drug Reactions
35/49
Most adverse reactions occur during thetreatment with:
DIGOXINE, ANTIBIOTICS, DIURETICS,POSTASSIUM, ANALGESICS, SEDATIVES ANDNEUROLEPTICS, INSULIN, ASPIRIN,GLUCOCORTICOIDS, ANTIHYPERTENSIVES AND
WARFARIN.
To recognize the adverse reaction is of sameimportance as to be able to make right diagnosisof a disease
8/10/2019 Adverse and Toxic Drug Reactions
36/49
TOXIC EFFECTS
8/10/2019 Adverse and Toxic Drug Reactions
37/49
Are induced by high single doses or long-termtherapy leading to high cumulative doses .
Doses/duration of treatment is supratherapeutic!
The safety for therapeutic use is defined by TI Drugs with low TI values are approved to get in to the
clinical practice only in the case of life-saving indicationswhere risks do not overweight the benefits
They can be induced and manifested by As extremely escalated therapeutic effects (e.g., overdose
with anticoagulant drugs induce life-threatening bleeding By totally different mechanisms and symptoms with no
relationship to pharmacological actionCovalent interactions often occur with destruction of
biomolecules and histopathological findings which might beirreversible
Toxic drug effects
8/10/2019 Adverse and Toxic Drug Reactions
38/49
Toxic effects
Possible molecular consequences of the drug-induced toxicity ROS production (often the metabolite is reactive
radical) with subsequent oxidative damage tobiomolecules (lipids, proteins, DNA) Ca 2+ overload activation of Ca-dependent
proteases, Ca accumulation in mitochondria andimpact on MPTP depolarization ofmitochondria
Impaired ATP production Direct impact on gene expression Activation of proteolytic cascades Triggering of apoptosis
8/10/2019 Adverse and Toxic Drug Reactions
39/49
Toxic effects
Prevention : reduction of individual dose,number of individual dosage forms, monitoringof pharmacotherapy
Treatment: Non-specific treatment: to prevent or reduce
further drug absorption, to accelerate drugelimination and support of vital functions
Specific treatment: with antidotes takingadvantage of specific antagonisms (mostlypharmacological)
8/10/2019 Adverse and Toxic Drug Reactions
40/49
Evaluation of toxiceffects of drugs
Overlap of pharmacology and toxicologyParacelsus postulateMUST involve in vivo testing on experimental animals In vitro testing has only limited values for regulatory purposes
Indispensable part of preclinical files of each drug which should be Approved for testing on human beings Approved for use in clinical practice
Acute toxicity studies (TD 50 , LD50 TI determination), subchronic toxicitystudies (90 days) and chronic toxicity studies (at least 1 year) Choice of animal species, strain, age, sex is of critical importance Control group receives only drug vehicle, otherwise all must be same as in
the tested group Animal randomization into the groups (tested and control) After repeated administration testing the investigators look for the signs of
drug accumulation, link to toxicokinetics
Evaluated parameters: general toxicity e.g., changes in appearance,behavior, weight gain
Identification of target organ toxicities using histopathological anbiochemical, hematological approaches
8/10/2019 Adverse and Toxic Drug Reactions
41/49
Drugs and organ toxicity
Nephrotoxicity Aminoglycosides, cyclosporin, ACE-inhibitors, NSAIDs,
cisplatin, amphotericin B, paracetamolHepatotoxicity
Paracetamol, isoniazid, halothan, methotrexateNeurotoxicity vinca alcaloidsOtotoxicity gentamicin, furosemideCardiotoxiicty
anthracyclines, trastuzumab, tytosinkinase inhibitors,catecholamines digoxin, antiarrhythmics
GIT-toxicity NSAIDs, cytostaticsPhototoxicity piroxicam, diclofenac a sulfonamides,
hydrochlorothiazide
8/10/2019 Adverse and Toxic Drug Reactions
42/49
Special attention must be paid on elderly patients andpatients with prior kidney diseaseRenal function biomarker: creatininemia
Aminoglycosides : active (saturable) transport into thetubular cells ROS production, lysosomal enlargement and phospholipids
inside, apoptosis tubular toxicity
Reduced glomerular filtration, increasedcreatinineamia, and blood urea renal failure!
Once daily Special risks in newborn (esp. Immature)
TDM
Drugs and organ toxicity- nephrotoxicity
8/10/2019 Adverse and Toxic Drug Reactions
43/49
Drugs and organ toxicity- nephrotoxicity
Tubular toxicity also in: cisplatin, vankomycinEndotelial toxicity: cyclosporin, tacrolimusDecreased renal perfusion (due to the vasoconstriction):NSAIDs, cyclosporin, tacrolimus, amphotericine BCrystaluria: sulfonamides, acyclovir
NSAIDs:1. Single high dose induced acute renal failure with oligouria
(due to the vasoconstriction and drop in GF)2. Chronic analgesic nephropathy papillary necrosis,
chronic interstitial nephritis (ischemia?). Irreversibility !!!3. Interstitial nephritis (rare) increased creatininemia with
proteinuria (reversible, return to normal after 1-3 months
8/10/2019 Adverse and Toxic Drug Reactions
44/49
Cyclosporin Acute reversible renal dysfunction (due to the
vasoconstriction) Acute vasculopathy (non-inflammatory injury to
arterioles and glomerulus) Chronic nephropathy with interstitial fibrosisRenal hypertension is frequent!!!!
Cisplatin acute and chronic renal failure (focalnecrosis in in multiple segments of the nephron)Paracetamol in overdose: necrosis of cells ofproximal tubulesACE-inhibitors in higher doses, esp.captopril, in bilateral stenosis of renal artery
risk of severe acute renal failure
Drugs and organ toxicity- nephrotoxicity
8/10/2019 Adverse and Toxic Drug Reactions
45/49
The most important case: paracetamoloverdose Paracetamol is a very safe drug in normal doses (OTC
drug) However, in overdose (10-15g in a healthy adults) it leads
to life-threatening hepatotoxicity and nephrotoxicityResponsible is a reactive metabolite N-acetyl-p-benzoquinonimin , which oversaturates its detoxification metabolism basedon conjugation with GSHThis triggers a severe oxidative stress in hepatocytes whichresults in to the damage of biomolecules and necrotic celldeath of hepatocyteRisk factors age (more likely in children), alcoholism, liverdisease in anamnesisTreatment: acetylcysteine i.v. ASAP donates SH to reduce GSHdepletion in the liver
Drugs and organ toxicity- hepatotoxicity
8/10/2019 Adverse and Toxic Drug Reactions
46/49
Risk of hepatocellular necrosis also in:halothan and isoniazid
Hepatic cirrhosis/fibrosis methotrexateafter long-term use
Cholestatic hepatitis: chlorpomazine,estrogens, cyclosporin
Drugs and organ toxicity- hepatotoxicity
8/10/2019 Adverse and Toxic Drug Reactions
47/49
Ac-glucuronide Ac Ac-sulfate
Reactive electrophiliccompound (NAPBQI*)
GSH Cell macromolecules(proteins)
GS-NAPBQI NAPBQI-protein
Ac-mercapturate Hepatic cell death
Hepatotoxicity of paracetamol
8/10/2019 Adverse and Toxic Drug Reactions
48/49
Impaired cardiac function induction of arrhythmias Most of antiarrhythmics have also
proarhythmogenic effects DAD after digoxin bigeminias, trigeminias etc
Methylxantins theophylline Tricyclic antidepressants - amitriptyline Drug-induced long QT syndrome - predisposition
for polymorphic ventricular arrhythmias of the
torsade de point type, which may be fatalSafety pharmacology- QT interval testing in new drugsReason for drug withdrawal from market in many cases:cisapride, terfenadine The risk is present in some currently prescribed drugs:
drugs in psychiatry: some antidepressants andantipsychotics, macrolides, fluoroquinolones
Drugs and organ toxicity- cardiotoxicity
8/10/2019 Adverse and Toxic Drug Reactions
49/49
Drugs and organ toxicity- cardiotoxicity
Induction of cardiomyopathy and/or chronicheart failure
Anthracyclines, trastuzumab, tyrosinkinaseinhibitors (sunitinib), tacrolimus, reversetranscriptase inhibitors Anthracycline cardiotoxicity
Acute mostly subclinical ECG changesSubacute myocarditis-pericarditis (rarely seen)Chronic (within 1 year)Delayed (late onset, 1-20 years after the chemotherapy)
Chronic and delayed forms depend on the cumulative dose Options for prevention: pharmacological cardioprotection with
dexrazoxane, targeted distribution of anthracyclines(liposomes)